A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-15. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
In the process, he found that a precipitation of thorium A (polonium-216) and thorium B (lead-212) also contained a short-lived "element", which he named thorium C (which was later identified as polonium-212). Hahn was unable to separate it, and concluded that it had a very short half-life (it is about 300 ns). He also identified radioactinium (thorium-227) and radium D (later identified as lead-210). Rutherford remarked that: "Hahn has a special nose for discovering new elements."
=== Weaning === During weaning, decreased prolactin, missing mechanical stimulation (baby suckling), and changes in osmotic balance caused by milk stasis and leaking of tight junctions cause cessation of milk production. It is the (passive) process of a child or animal ceasing to be dependent on the mother for nourishment. In some species there is complete or partial involution of alveolar structures after weaning, in humans there is only partial involution and the level of involution in humans appears to be highly individual. The glands in the breast do secrete fluid also in nonlactating women. In some other species (such as cows), all alveoli and secretory duct structures collapse by programmed cell death (apoptosis) and autophagy for lack of growth promoting factors either from the ECM or circulating hormones. At the same time, apoptosis of blood capillary endothelial cells speeds up the regression of lactation ductal beds. Shrinkage of the mammary duct tree and ECM remodeling by various proteinase is under the control of somatostatin and other growth inhibiting hormones and local factors. This major structural change leads loose fat tissue to fill the empty space afterward. But a functional lactiferous duct tree can be formed again when a female is pregnant again.
=== Energy supplements === Athletes sometimes turn to energy supplements to increase their ability to exercise more often. Common supplements to increase an athlete's energy include: Caffeine, Guarana, Vitamin B12, and Asian ginseng. Guarana is another supplement that athletes take to enhance their athletic ability, it is frequently used for weight loss and as an energy supplement. Caffeine, a common energy supplement, can be found in many different forms such as pills, tablets or capsules, and can also be found in common foods, such as coffee and tea. A 2009 study from the University of Texas reports that caffeinated energy drinks increase sporting performance. They found that after drinking an energy drink, 83% of participants improved their physical activity parameters by an average of 4.7%. This was attributed to the effects of caffeine, sucrose and Vitamin B in the drink - however scientific consensus does not support the efficacy of using Vitamin B as a performance enhancer. To explain the performance improvement the writers report an increase in blood levels of epinephrine, norepinephrine and beta-Endorphin. The adenosine receptor antagonism of caffeine accounts for the first two, while the latter is accounted for by the Neurobiological effects of physical exercise. The effectiveness of caffeine to mask fatigue has been explored since the early 1900s and its use in sports nutrition became popular in the 1970s when this effect became highly recognized.
Fluorodeoxyglucose ([18F]FDG or FDG) is commonly used to detect cancer, as cancer cells need sugar to grow. [18F]Sodium fluoride (Na18F) is widely used for detecting bone formation. Oxygen-15 (15O)-water is used to quantify myocardial blood flow. Carbon-11 (11C)-methionine is used to image brain tumors.
Sources: en.wikipedia.org
It found that pseudoephedrine had a small risk of insomnia and this was the only side effect that occurred at rates significantly different from placebo. Insomnia occurred at a rate of 5% and had an odds ratio (OR) of 6.18. Other side effects, including headache and hypertension, occurred at rates of less than 4% and were not different from placebo. Tachyphylaxis is known to develop with prolonged use of pseudoephedrine, especially when it is re-administered at short intervals. There is a case report of temporary depressive symptoms upon discontinuation and withdrawal from pseudoephedrine. The withdrawal symptoms included worsened mood and sadness, profoundly decreased energy, a worsened view of oneself, decreased concentration, psychomotor retardation, increased appetite, and increased need for sleep. Pseudoephedrine has psychostimulant effects at high doses and is a positive reinforcer with amphetamine-like effects in animals including rats and monkeys. However, it is substantially less potent than methamphetamine or cocaine.
National teams June 3 – 9: 2019 FIBA Under-16 Americas Championship in Belém The United States defeated Canada, 94–77, to win their sixth consecutive FIBA Under-16 Americas Championship title. The Dominican Republic took third place. Argentina took fourth place. Note: All teams mentioned above have qualified to compete at the 2020 FIBA Under-17 Basketball World Cup. June 16 – 22: 2019 FIBA Under-16 Women's Americas Championship in Puerto Aysén The United States defeated Canada, 87–37, to win their second consecutive and fifth overall FIBA Under-16 Women's Americas Championship title. Chile took third place. Puerto Rico took fourth place. Note: All teams mentioned above have qualified to compete at the 2020 FIBA Under-17 Women's Basketball World Cup. September 22 – 29: 2019 FIBA Women's AmeriCup in San Juan The United States defeated Canada, 67–46, to win their third FIBA Women's AmeriCup title. Brazil took third place. Note: The first eight teams have qualified to compete at the Americas 2020 Olympic pre-qualifying tournaments. Club teams January 18 – March 31: 2019 FIBA Americas League San Lorenzo defeated Guaros, 64–61, to win their second consecutive FIBA Americas League title.
The move resulted in a backlash from the gaming community, and Firewatch was "review-bombed" on Steam. Ars Technica noted that the company previously stated on their website that they gave open permission to stream and monetize videos made while playing the game. On April 21, 2018, Campo Santo announced that they had been acquired by Valve and would subsequently move to Valve's Bellevue, Washington headquarters and continuing In the Valley of Gods as a Valve game. According to Vanaman and Rodkin, after the success of Firewatch, they started internal discussions of where they wanted to take their company. These discussions continued informally with third parties, including Valve's Robin Walker, Erik Johnson and Scott Lynch. These Valve employees suggested that Campo Santo could retain its own direction while being wholly within Valve, yet still draw from Valve's knowledge and expertise. Vanaman and Rodkin discussed this more formally with Valve, ultimately leading to the acquisition. Development on In The Valley of Gods was put on hold in July 2019, partially due to head writer Sean Vanaman moving to the writing team for Half-Life: Alyx, which had not been announced to the public at the time. In November 2019, it was noted by journalists that Claire Hummel, Jane Ng, and Rodkin had removed In the Valley of Gods from their Twitter profile descriptions. The game also disappeared from Campo Santo's website and the original announcement trailer was made private on YouTube, though the website and its Steam profile page were still available.
== Premise == The show's plot centers around the lives of half-sisters Mona and Dee Dee Thorne, who slowly become friends when they move into the same San Francisco apt building. Mona is the daughter of Phyllis Thorne, Charles Thorne's first wife, and Dee Dee is Charles' daughter from his second marriage to Deirdre "Big Dee Dee" Thorne. Initially, Mona resents Dee Dee because Dee Dee grew up in a wealthy and privileged household, while Mona and her mother struggled financially. As adults, Mona is more street-smart and cynical, but prone to impulsive decisions while Dee Dee is charming and optimistic, but naïve at times. Throughout the series, the sisters confront their past resentments and learn to lean on each other as they navigate their issues in work, love, and family.
Italian forces entered British Somaliland from Abyssinia on 4 August 1940, overcame the garrison at Hargeisa, and advanced north-east towards the capital Berbera. The British force, including a platoon of 43 Rhodesians in the 2nd Battalion of the Black Watch, took up positions on six hills overlooking the only road towards Berbera and engaged the Italians at the Battle of Tug Argan. Amid heavy fighting, the Italians gradually made gains and by 14 August had almost pocketed the Commonwealth forces. The British retreated to Berbera between 15 and 17 August, the Rhodesians making up the left flank of the rearguard, and by 18 August had evacuated by sea. The Italians took the city and completed their conquest of British Somaliland a day later. No. 237 Squadron embarked on reconnaissance flights and supported ground assaults on Italian desert outposts during July and August 1940. Two British brigades from West Africa arrived to reinforce Kenya's northern frontier in early July—the partly Rhodesian-officered Nigeria Regiment joined the front at Malindi and Garissa, while a battalion of the Gold Coast Regiment, also with Rhodesian commanders attached, relieved the KAR at Wajir. The British forces in East Africa adopted the doctrine of "mobile defence" that was already being used in the Western Desert in North Africa—units embarked on long, constant patrols to guard wells and deny water supplies to the Italians. The British evacuated their north forward position at Buna in September 1940, and expected an attack on Wajir soon after, but the Italians never attempted an assault.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.